![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Thermo Fisher to Help Manufacture Humanigen's COVID-19 Therapeutic Lenzilumab
Thermo Fisher to Help Manufacture Humanigen's COVID-19 Therapeutic Lenzilumab
![team up](https://www.fdanews.com/ext/resources/test/Device_Images5/team-up-text.gif?t=1590011221&width=430)
September 25, 2020
Humanigen has teamed up with Massachusetts-based Thermo Fisher Scientific, which will help manufacture the drug substance for Humanigen’s COVID-19 monoclonal antibody lenzilumab.
The partnership is intended to scale up commercial production efforts in advance of a potential Emergency Use Authorization (EUA) from the FDA in 2020 and a subsequent approval. Thermo Fischer expects to begin commercial-scale production of the lenzilumab bulk drug substance before the end of the year.
Lenzilumab is currently in phase 3 testing in the U.S. for prevention of cytokine storms in COVID-19 patients.
Upcoming Events
-
21Oct